Dyslipidemia is frequently associated with insulin resistance or high-fat dietary patterns, characterized by hepatic nuclear receptor signaling dysregulation, specifically involving the suppression of the FXR-small heterodimer partner (SHP) pathway and subsequent up-regulation of CYP7A1 expression, ultimately precipitating enhanced primary cholic acid biosynthesis.36 The gene discussed is NR0B2; the disease is metabolic syndrome.